Amphotericin - lipid associated

C. diff Risk


Oral Bioavailability


Spectrum Of Activity


Ambisome - 3-6mg/kg IV daily infused over several hours

Abelcet - 5mg/kg IV daily infused over several hours

No dose adjustment recommended

Ambisome and Abelcet - 3-5mg/kg IV daily.

General Information

Renal function, K, Mg, HCO3, liver enzymes, CBC.

Frequency depends on course, but daily reasonable during initiation

Same toxicities as conventional Amphotericin B but with less frequency

Infusion related symptoms: fever/rigors/N/V/headache (see additional information)

Electrolyte abnormalities - hypoK and hypoMg, loss of bicarb (see additional information re: electrolyte infusions)

Nephrotoxicity ++



Urinary retention


Main concern is concomitant nephrotoxins - use should be minimized during amphotericin therapy

Digoxin - increased digoxin toxicity with hypokalemia

Must be approved by Infectious Disease.

Lipid associated AmB is taken up preferentially by phagocytic cells and concentrated at sites of infection while minimizing renal exposure

Careful attention to electrolyte and fluid status with boluses (usually 500mL) before and after infusion, as well as K and Mg supplementation PRN

Antimicrobial class: Antifungal - polyene - Lipid formulations (designed to minimize toxicity)

Average serum half life: 150.0

Biliary penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Poor

Fungicidal therapy of yeast/fungus/mold infection (not for use in urinary tract infection)

Invasive candidiasis, aspergillosis, cryptococcosis

Visceral/mucocutaneous Leishmaniasis

Induction therapy for dimorphic fungii (cocci, blasto, histo)